Acamprosate Initiated During Alcohol Detoxification
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
Acamprosate is approved by the Food and Drug Administration (FDA) for the treatment of
alcoholism. The purpose of this study is to see if initiating acamprosate early in alcohol
detoxification instead of waiting until detoxification has been completed effects the course
of detoxification, adverse events during detoxification, drop out rate during the
rehabilitative treatment phase, or overall efficacy of acamprosate for those with alcohol
dependence who plan to receive at least two months of rehabilitative pharmacotherapy with
acamprosate.